Organogenesis director buys 5,000 shares in open market
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
Leibowitz Arthur S
Role
Director
Bought
5,000 shs ($13K)
Increase in Position
1.7%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 5,000 | $2.681 | $13K |
Holdings After Transaction:
Class A Common Stock — 291,014 shares (Direct)
Holdings Before and After:
Class A Common Stock, 286,014 to 291,014 shares (Direct)
Other Insiders: 1 other insider reported open-market purchases of this stock in the 30 days up to this filing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Organogenesis (ORGO) report for Arthur S. Leibowitz?
Organogenesis reported that director Arthur S. Leibowitz made an open-market purchase of 5,000 shares of Class A common stock on March 9, 2026. This transaction increased his directly owned stake to 291,014 shares, signaling an additional personal capital commitment.
Was the Organogenesis (ORGO) insider trade a purchase or a sale?
The reported insider trade was a purchase. Director Arthur S. Leibowitz executed an open-market buy of 5,000 shares of Organogenesis Class A common stock at $2.681 per share, increasing his direct ownership to a total of 291,014 shares following the transaction.
What type of security did the Organogenesis (ORGO) insider acquire?
Arthur S. Leibowitz acquired Class A common stock of Organogenesis. The Form 4 specifies the transaction involved 5,000 non-derivative shares purchased in the open market, which raised his directly owned holdings of this common equity class to 291,014 shares in total.
AI-generated analysis. How Rhea-AI works. Not financial advice.